Exscientia Revenue and Competitors
Estimated Revenue & Valuation
- Exscientia's estimated annual revenue is currently $90.2M per year.
- Exscientia's estimated revenue per employee is $758,067
Employee Data
- Exscientia has 119 Employees.
- Exscientia grew their employee count by -76% last year.
Exscientia's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EA to CQMO and VP Precision Medicine | Reveal Email/Phone |
2 | Executive Assistant to CQMO and EVP to Precision Medicine | Reveal Email/Phone |
3 | VP Development Operations | Reveal Email/Phone |
4 | VP Corporate Communications | Reveal Email/Phone |
5 | Director, Engagement Lead | Reveal Email/Phone |
6 | Associate Director | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Associate Director, Small Molecule Design | Reveal Email/Phone |
9 | Director Clinical Operations NIT & Dx | Reveal Email/Phone |
10 | Places-, Event-, Hospitality Manager | Reveal Email/Phone |
Exscientia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1M | 12 | N/A | N/A | N/A |
#2 | $24.3M | 177 | 27% | $275M | $3.2B |
What Is Exscientia?
At the forefront of small molecule drug discovery We are the first company to automate drug design, surpassing conventional human endeavour. Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
keywords:N/A
N/A
Total Funding
119
Number of Employees
$90.2M
Revenue (est)
-76%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Exscientia News
Exscientia's AI platform is used to identify promising molecules that can proceed to the next step of drug development by large...
Exscientia scientists will present new research in three poster presentations. We are looking forward to meeting with some of the world's...
Exscientia's drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for...
With two partnered drugs in the clinic, Exscientia is reeling in up to $525 million to push its own pipeline into clinical testing and continue developing an artificial intelligence-based technology toward autonomous drug design. Oxford, U.K.-based Exscientia started out inking drug discovery d ...
28/4/2021 Exscientia announces investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia's discretion Financing led by SoftBank V ...
Other Companies in Oxford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29.3M | 119 | -2% | N/A |
#2 | $90.2M | 119 | -76% | N/A |
#3 | $26M | 119 | 14% | N/A |
#4 | $39.3M | 119 | 20% | N/A |
#5 | $16.5M | 121 | 33% | N/A |